Korro Bio starts dosing in KRRO-121 trial, faces Novo Nordisk termination
Korro reported dosing of healthy volunteers in its ANCHOR trial and preclinical data for KRRO-111, while disclosing Novo Nordisk's move to terminate their collaboration agreement effective February 1, 2027.
SEC filing